All In Biotech

Investigational drug · Phase 3

SAR445088

Also called: Riliprubart, BIVV020, Riliprubart Prefilled, PFP

Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Polyneuropathy, Inflammatory Demyelinating, Chronic, Transplant Rejection.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

5

4 still active

All registered trials

7

Any phase or sponsor naming "SAR445088"

First trial start

2021

Apr 28, 2021

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "SAR445088", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Polyneuropathy, Inflammatory Demyelinating, Chronic
  • Transplant Rejection
  • Chronic Inflammatory Demyelinating Polyneuropathy

Approved drugs for the same conditions: Neurology

Largest trials

Live from ClinicalTrials.gov: studies naming "SAR445088" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2,994 on PubMed

Also in development for Chronic Inflammatory Demyelinating Polyradiculoneuropathy

  • EmpasiprubartARGX-117Phase 39 trials

    argenx · Multifocal Motor Neuropathy (MMN), Chronic Inflammatory Demyelinating Polyneuropathy, CIDP

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.